share_log

Vertex Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Capital World Investors(10.0%)

Vertex Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

福泰制药 | SC 13G/A：超过5%持股股东披露文件(修正)
SEC announcement ·  04/10 12:17
Moomoo AI 已提取核心信息
Capital World Investors (CWI), a division of Capital Research and Management Company, has filed an amendment with the United States Securities and Exchange Commission (SEC) on April 10, 2024, indicating that they hold a 10% ownership stake in Vertex Pharmaceuticals Inc. The Schedule 13G filing, specifically under Rule 13d-1(b), shows that CWI possesses sole voting power over 25,811,092 shares and sole dispositive power over 25,902,938 shares of Vertex Pharmaceuticals' common stock. This represents a significant position in the company, with CWI being deemed the beneficial owner of these shares. The filing was made to comply with SEC regulations that require disclosure when certain thresholds of ownership in a publicly-traded company are reached or exceeded. The address for Vertex Pharmaceuticals is listed as 50 Northern Avenue, Boston, MA 02210, and the CUSIP number for the common stock is 92532F100. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Vertex Pharmaceuticals.
Capital World Investors (CWI), a division of Capital Research and Management Company, has filed an amendment with the United States Securities and Exchange Commission (SEC) on April 10, 2024, indicating that they hold a 10% ownership stake in Vertex Pharmaceuticals Inc. The Schedule 13G filing, specifically under Rule 13d-1(b), shows that CWI possesses sole voting power over 25,811,092 shares and sole dispositive power over 25,902,938 shares of Vertex Pharmaceuticals' common stock. This represents a significant position in the company, with CWI being deemed the beneficial owner of these shares. The filing was made to comply with SEC regulations that require disclosure when certain thresholds of ownership in a publicly-traded company are reached or exceeded. The address for Vertex Pharmaceuticals is listed as 50 Northern Avenue, Boston, MA 02210, and the CUSIP number for the common stock is 92532F100. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Vertex Pharmaceuticals.
资本研究与管理公司旗下的资本世界投资者（CWI）已于2024年4月10日向美国证券交易委员会（SEC）提交了一项修正案，表示他们持有Vertex Pharmicals Inc.10％的所有权。附表13G文件，特别是根据第13d-1（b）条提交的文件显示，CWI拥有对25,811,092股股票的唯一处置权 Vertex Pharmaceuticals的38股普通股。这代表了公司的重要地位，CWI被视为这些股票的受益所有人。该文件是为了遵守美国证券交易委员会的规定，该法规要求在达到或超过上市公司的某些所有权门槛时进行披露。Vertex Pharmicals的地址被列为马萨诸塞州波士顿北大道50号02210，普通股的CUSIP编号为 92532F100。该文件称，这些股份是在正常业务过程中收购的，不是为了改变或影响Vertex Pharmicals的控制权。
资本研究与管理公司旗下的资本世界投资者（CWI）已于2024年4月10日向美国证券交易委员会（SEC）提交了一项修正案，表示他们持有Vertex Pharmicals Inc.10％的所有权。附表13G文件，特别是根据第13d-1（b）条提交的文件显示，CWI拥有对25,811,092股股票的唯一处置权 Vertex Pharmaceuticals的38股普通股。这代表了公司的重要地位，CWI被视为这些股票的受益所有人。该文件是为了遵守美国证券交易委员会的规定，该法规要求在达到或超过上市公司的某些所有权门槛时进行披露。Vertex Pharmicals的地址被列为马萨诸塞州波士顿北大道50号02210，普通股的CUSIP编号为 92532F100。该文件称，这些股份是在正常业务过程中收购的，不是为了改变或影响Vertex Pharmicals的控制权。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息